A clinical case report in Oncotarget documents durable complete response in central nervous system (CNS) disease for a patient with rare EGFR-mutated non-small cell lung cancer treated with amivantamab monotherapy after progression on osimertinib. At six months, MRI showed complete resolution of brain metastases, demonstrating effective targeting of rare EGFR mutations and blood-brain barrier penetration. This case expands therapeutic options for patients with uncommon mutations facing limited treatments.